Adma Biologics (ADMA) Change in Receivables (2011 - 2025)

Adma Biologics' Change in Receivables history runs 13 years deep, the most recent figure standing at $20.8 million for Q4 2025.

• Quarterly Change in Receivables rose 14820.57% year-over-year to $20.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $108.4 million (up 380.25% YoY) and the FY2025 annual result came in at $108.4 million, up 380.25% from the prior year.
• Change in Receivables was $20.8 million for Q4 2025 at Adma Biologics, down from $27.9 million in the prior quarter.
• Across five years, Change in Receivables topped out at $49.4 million in Q1 2025 and bottomed at -$19.5 million in Q2 2024.
• A 5-year average of $7.3 million and a median of $5.2 million in 2021 frame the typical range for Change in Receivables.
• Annual changes were most pronounced in 2021 — Change in Receivables tumbled 1654.71% — and 2025, when it jumped 14820.57%.
• Adma Biologics' Change in Receivables stood at $8.2 million in 2021, then tumbled by 165.95% to -$5.4 million in 2022, then grew by 27.78% to -$3.9 million in 2023, then surged by 96.38% to -$141000.0 in 2024, then soared by 14820.57% to $20.8 million in 2025.
• Business Quant data shows ADMA's Change in Receivables at $20.8 million in Q4 2025, $27.9 million in Q3 2025, and $10.3 million in Q2 2025.